Early rheumatoid arthritis

Purpose of reviewThis review provides novel and updated information on pathogenesis, referral, and clinical characteristics as well as therapeutic approaches in early rheumatoid arthritis. Recent findingsEarly referral is important, but new classification criteria for early rheumatoid arthritis need to be elaborated. Predictive markers for rheumatoid arthritis are still confined to autoantibodies; respective algorithms have been presented. Other biomarkers will still have to prove their usefulness. Magnetic resonance imaging and sonography do not appear to sufficiently distinguish between early rheumatoid and nonrheumatoid arthritis. Rheumatoid arthritis has become milder at presentation in recent years. In its very early stages, the cytokine profile reflects T-cell activation and switches to abundant proinflammatory cytokines thereafter. Disease-modifying antirheumatic drugs plus glucocorticoids are highly effective, as is early use of tumor necrosis factor blockers plus methotrexate. Tight control of disease activity and subsequent therapeutic adjustments are highly effective. Disease activity indices that are simple to calculate have been presented and validated. Early intensive therapy may lead to decrease in disability and cost reduction in rheumatoid arthritis. SummaryUnderstanding of early arthritis is increasing, especially in prognostic and therapeutic respects, and new treatment strategies appear to improve the outcome in patients with early arthritis. Nevertheless, much remains to be studied to better address the issue of early rheumatoid arthritis.

[1]  P. V. van Riel,et al.  Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis. , 2005, Arthritis and rheumatism.

[2]  M. Uffmann,et al.  Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. , 2006, Rheumatology.

[3]  Ø. Palm,et al.  Women with early rheumatoid arthritis are referred later than men , 2005, Annals of the rheumatic diseases.

[4]  A M Walker,et al.  The lag time between onset of symptoms and diagnosis of rheumatoid arthritis. , 1994, Arthritis and rheumatism.

[5]  J. Smolen,et al.  The Austrian Early Arthritis Registry. , 2003, Clinical and experimental rheumatology.

[6]  A. Silman,et al.  The performance of the 1987 ARA classification criteria for rheumatoid arthritis in a population based cohort of patients with early inflammatory polyarthritis. American Rheumatism Association. , 1998, The Journal of rheumatology.

[7]  Y. Ishigatsubo,et al.  Bone erosions in rheumatoid arthritis can be repaired through reduction in disease activity with conventional disease-modifying antirheumatic drugs , 2006, Arthritis research & therapy.

[8]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[9]  A. Silman,et al.  Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort. , 2002, Arthritis and rheumatism.

[10]  A. Zwinderman,et al.  Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. , 2001, The American journal of medicine.

[11]  M. Dougados,et al.  Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. , 2001, Arthritis and rheumatism.

[12]  P. Jones,et al.  Patterns of radiological progression in early rheumatoid arthritis: results of an 8 year prospective study. , 1998, The Journal of rheumatology.

[13]  D. Symmons.  Classification criteria for rheumatoid arthritis--time to abandon rheumatoid factor? , 2007, Rheumatology.

[14]  A. Silman,et al.  Cases of early inflammatory polyarthritis should not be classified as having rheumatoid arthritis. , 2003, The Journal of rheumatology.

[15]  H. Tiwari,et al.  The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. , 2004, Arthritis and rheumatism.

[16]  J. Smolen,et al.  Attitudes to early rheumatoid arthritis: changing patterns. Results of a survey , 2004, Annals of the rheumatic diseases.

[17]  M. V. van Leeuwen,et al.  Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. , 1997, The Journal of rheumatology.

[18]  J. Fries,et al.  An analysis of the American Rheumatism Association criteria for rheumatoid arthritis. , 1982, Arthritis and rheumatism.

[19]  F. Wolfe,et al.  Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. , 2002, Rheumatology.

[20]  Differentiating persistent from self-limiting symmetrical synovitis in an early arthritis clinic. , 1993, British journal of rheumatology.

[21]  R. Rau,et al.  Identification of radiologic healing phenomena in patients with rheumatoid arthritis. , 2001, The Journal of rheumatology.

[22]  M. Pillinger.  Very Early Treatment With Infliximab in Addition to Methotrexate in Early, Poor-Prognosis Rheumatoid Arthritis Reduces Magnetic Resonance Imaging Evidence of Synovitis and Damage, With Sustained Benefit After Infliximab Withdrawal: Results From a Twelve-Month Randomized, Double-blind, Placebocontrol , 2006 .

[23]  F. Breedveld,et al.  The need for new classification criteria for rheumatoid arthritis. , 2005, Arthritis and rheumatism.

[24]  Saskia Le Cessie,et al.  Using predicted disease outcome to provide differentiated treatment of early rheumatoid arthritis. , 2006, The Journal of rheumatology.

[25]  Richard W. Martin,et al.  Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. , 2005, The Journal of rheumatology.

[26]  C. Gordon,et al.  Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin , 2005, Arthritis research & therapy.

[27]  Michael H Weisman,et al.  New therapies for treatment of rheumatoid arthritis , 2007, The Lancet.

[28]  Richard W. Martin,et al.  A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. , 2000, The New England journal of medicine.

[29]  A. Cotten,et al.  MR imaging findings in hands in early rheumatoid arthritis: comparison with those in systemic lupus erythematosus and primary Sjögren syndrome. , 2005, Radiology.

[30]  J. Kirwan,et al.  The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. , 1995, The New England journal of medicine.

[31]  G. Firestein,et al.  How important are T cells in chronic rheumatoid synovitis?: II. T cell-independent mechanisms from beginning to end. , 2002, Arthritis and rheumatism.

[32]  F. Breedveld,et al.  p53 overexpression in synovial tissue from patients with early and longstanding rheumatoid arthritis compared with patients with reactive arthritis and osteoarthritis. , 1999, Arthritis and rheumatism.

[33]  D. Green,et al.  Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[34]  A. McMahon,et al.  Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial , 2004, The Lancet.

[35]  Koen Vos,et al.  How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. , 2002, Arthritis and rheumatism.

[36]  M. Boers.  The case for corticosteroids in the treatment of early rheumatoid arthritis. , 1999, Rheumatology.

[37]  I. F. Duff,et al.  Estimates of the prevalence of rheumatic diseases in the population of Tecumseh, Michigan, 1959-60. , 1967, Journal of chronic diseases.

[38]  T. Pincus,et al.  Rheumatoid arthritis identified in population based cross sectional studies: low prevalence of rheumatoid factor. , 1991, The Journal of rheumatology.

[39]  F. Breedveld,et al.  Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. , 2004, Arthritis and rheumatism.

[40]  D A Bloch,et al.  The progression of erosion and joint space narrowing scores in rheumatoid arthritis during the first twenty-five years of disease. , 1991, Arthritis and rheumatism.

[41]  B Combe,et al.  EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) , 2006, Annals of the rheumatic diseases.

[42]  Saskia le Cessie,et al.  A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. , 2007, Arthritis and rheumatism.

[43]  E. Matteson,et al.  How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to 'non-aggressive' DMARD treatment and perspective from a 2-yr open label trial. , 2004, Rheumatology.

[44]  P. Gregersen,et al.  The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. , 1987, Arthritis and rheumatism.

[45]  M. Dougados,et al.  The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. , 1991, Arthritis and rheumatism.

[46]  A. Boonen,et al.  Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. , 2005, Arthritis and rheumatism.

[47]  H. Heinzl,et al.  Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis , 2005, Annals of the rheumatic diseases.

[48]  D. Heijde.  Joint erosions and patients with early rheumatoid arthritis , 1995 .

[49]  F. Breedveld,et al.  Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. , 1997, Arthritis and rheumatism.

[50]  P. Hannonen,et al.  Healing of erosions in rheumatoid arthritis , 2000, Annals of the rheumatic diseases.

[51]  Tanja Stamm,et al.  Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. , 2005, Arthritis and rheumatism.

[52]  Michael J. Green,et al.  Persistence of mild, early inflammatory arthritis: the importance of disease duration, rheumatoid factor, and the shared epitope. , 1999, Arthritis and rheumatism.

[53]  Cynthia S Crowson,et al.  Prognostic markers of radiographic progression in early rheumatoid arthritis. , 2004, Arthritis and rheumatism.

[54]  B. Bresnihan,et al.  Disease-modifying anti-rheumatic drug therapy and structural damage in early rheumatoid arthritis. , 2003, Clinical and experimental rheumatology.

[55]  M. Dougados,et al.  Development of classification and response criteria for rheumatic diseases. , 2006, Arthritis and rheumatism.

[56]  T. Pincus,et al.  Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. , 1984, Arthritis and rheumatism.

[57]  Hyon K. Choi,et al.  Predicting mortality in patients with rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[58]  R. Holmdahl,et al.  Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis , 2005, European journal of immunology.

[59]  J. Kirwan,et al.  Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial. , 2005, Archives of internal medicine.

[60]  Michael J. Green,et al.  Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol. , 2003, Arthritis and rheumatism.

[61]  A. Burls,et al.  A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis. , 2003, Rheumatology.

[62]  William G Dixon,et al.  Does early rheumatoid arthritis exist? , 2005, Best practice & research. Clinical rheumatology.

[63]  E. Keystone,et al.  Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. , 2004, Arthritis and rheumatism.

[64]  J. Smolen,et al.  The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. , 2002, Rheumatology.

[65]  A. Zwinderman,et al.  Long-term outcome in rheumatoid arthritis: a simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup. , 2002, Arthritis and rheumatism.

[66]  H. Paulus,et al.  Dating the "window of therapeutic opportunity" in early rheumatoid arthritis: accuracy of patient recall of arthritis symptom onset. , 2004, The Journal of rheumatology.

[67]  U. Brodin,et al.  Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. , 1995, The Journal of rheumatology.

[68]  Marcin Szkudlarek,et al.  Imaging in early rheumatoid arthritis: roles of magnetic resonance imaging, ultrasonography, conventional radiography and computed tomography. , 2005, Best practice & research. Clinical rheumatology.

[69]  J. Jacobs,et al.  Low-Dose Prednisone Therapy for Patients with Early Active Rheumatoid Arthritis: Clinical Efficacy, Disease-Modifying Properties, and Side Effects: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial , 2002, Annals of Internal Medicine.

[70]  B. Dijkmans,et al.  Combination therapy in recent onset rheumatoid arthritis: a randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine. , 1998, The Journal of rheumatology.

[71]  B. Dijkmans,et al.  Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. , 2005, Arthritis and rheumatism.

[72]  R. Rau,et al.  Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. , 2005, Arthritis and rheumatism.

[73]  J. Jacobs,et al.  Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial , 2000, Annals of the rheumatic diseases.

[74]  Andrew K. Brown,et al.  MRI and musculoskeletal ultrasonography as diagnostic tools in early arthritis. , 2005, Rheumatic diseases clinics of North America.

[75]  M. Uffmann,et al.  Patients and Methods , 2022 .

[76]  B. Dijkmans,et al.  Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. , 2004, Arthritis and rheumatism.

[77]  E. Keystone,et al.  Expression of interferon‐gamma (IFN‐δ), IL‐10, IL‐12 and transforming growth factor‐beta (TGF‐β) mRNA in synovial fluid cells from patients in the early and late phases of rheumatoid arthritis (RA) , 1996, Clinical and experimental immunology.

[78]  A. Silman,et al.  Natural remission in inflammatory polyarthritis: issues of definition and prediction. , 1996, British journal of rheumatology.

[79]  G. Kingsley,et al.  Treating rheumatoid arthritis early with disease modifying drugs reduces joint damage: a randomised double blind trial of sulphasalazine vs diclofenac sodium. , 2002, Clinical and experimental rheumatology.

[80]  Erik Waaler,et al.  On the occurrence of a factor in human serum activating the specific agglutintion of sheep blood corpuscles. 1939. , 2009, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[81]  T. Pincus,et al.  A proposed treatment algorithm for rheumatoid arthritis: aggressive therapy, methotrexate, and quantitative measures. , 2003, Clinical and experimental rheumatology.

[82]  R N Maini,et al.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.

[83]  E. Keystone,et al.  Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. , 2007, Arthritis and rheumatism.

[84]  P. Hannonen,et al.  Outcome in patients with early rheumatoid arthritis treated according to the "sawtooth" strategy. , 1996, Arthritis and rheumatism.

[85]  R. Madhok,et al.  Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial , 2004, Annals of the rheumatic diseases.

[86]  P. Taylor.  The value of sensitive imaging modalities in rheumatoid arthritis , 2003, Arthritis research & therapy.

[87]  F Guillemin,et al.  Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology , 2005, Annals of the rheumatic diseases.

[88]  M. Ahlmén,et al.  Treatment of early RA in clinical practice: a comparative study of two different DMARD/corticosteroid options. , 2003, Clinical and experimental rheumatology.

[89]  P. Hannonen,et al.  Conventional disease-modifying antirheumatic drugs in early arthritis. , 2005, Rheumatic diseases clinics of North America.

[90]  J. Smolen,et al.  Patients with rheumatoid arthritis in clinical care , 2004, Annals of the rheumatic diseases.

[91]  A. van der Heide,et al.  The Effectiveness of Early Treatment with Second-Line Antirheumatic Drugs , 1996, Annals of Internal Medicine.

[92]  S. van der Linden,et al.  Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis , 1997, The Lancet.

[93]  S. Rantapää-Dahlqvist.  Diagnostic and prognostic significance of autoantibodies in early rheumatoid arthritis , 2005, Scandinavian journal of rheumatology.

[94]  P. Tak.  Is early rheumatoid arthritis the same disease process as late rheumatoid arthritis? , 2001, Best practice & research. Clinical rheumatology.

[95]  G. Firestein.  Pathogenesis of rheumatoid arthritis: how early is early? , 2005, Arthritis research & therapy.

[96]  M. Uffmann,et al.  Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score , 2005, Arthritis research & therapy.

[97]  P. Hannonen,et al.  Predictors of productivity loss in early rheumatoid arthritis: a 5 year follow up study , 2004, Annals of the rheumatic diseases.

[98]  S. van der Linden,et al.  Arthritis instantaneously causes collagen type I and type II degradation in patients with early rheumatoid arthritis: a longitudinal analysis , 2005, Annals of the rheumatic diseases.

[99]  J. Smolen,et al.  Therapeutic strategies in early rheumatoid arthritis. , 2005, Best practice & research. Clinical rheumatology.

[100]  T. Saxne,et al.  Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis , 2003, Annals of the rheumatic diseases.

[101]  G. Schett,et al.  Tenosynovitis and osteoclast formation as the initial preclinical changes in a murine model of inflammatory arthritis. , 2007, Arthritis and rheumatism.

[102]  Neal Stewart,et al.  Magnetic resonance imaging evidence of tendinopathy in early rheumatoid arthritis predicts tendon rupture at six years. , 2005, Arthritis and rheumatism.

[103]  G. Verbruggen,et al.  Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity , 2000, Annals of the rheumatic diseases.

[104]  J. Crusius,et al.  Association between polymorphisms in the human chemokine receptor genes CCR2 and CX3CR1 and rheumatoid arthritis. , 2003, Tissue antigens.

[105]  Wei Chen,et al.  Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. , 2005, Arthritis and rheumatism.

[106]  M. Klarlund,et al.  Connective tissue metabolism in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity, bone mineral density, and radiographic outcome. , 2004, The Journal of rheumatology.

[107]  A. van Nieuwenhuijze,et al.  Time between onset of apoptosis and release of nucleosomes from apoptotic cells: putative implications for systemic lupus erythematosus , 2003, Annals of the rheumatic diseases.

[108]  F. Breedveld,et al.  Diagnosis and course of early-onset arthritis: results of a special early arthritis clinic compared to routine patient care. , 1998, British journal of rheumatology.

[109]  A. Silman,et al.  Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. , 2003, Arthritis and rheumatism.

[110]  J. Smolen,et al.  Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. , 2002, The Journal of rheumatology.

[111]  G. A. Bennett,et al.  1958 revision of diagnostic criteria for rheumatoid arthritis. , 1958, Arthritis and rheumatism.

[112]  J. Hazes,et al.  The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. , 2000, Arthritis and rheumatism.

[113]  F. Breedveld,et al.  Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. , 1995, Arthritis and rheumatism.

[114]  A. Silman,et al.  A simple algorithm to predict the development of radiological erosions in patients with early rheumatoid arthritis: prospective cohort study , 1996, BMJ.

[115]  Göran Hallmans,et al.  Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[116]  M. Uffmann,et al.  Very recent onset arthritis--clinical, laboratory, and radiological findings during the first year of disease. , 2002, The Journal of rheumatology.

[117]  D. M. van der Heijde,et al.  Imaging: do erosions heal? , 2003, Annals of the rheumatic diseases.

[118]  J. Cush.  Early arthritis clinic: a USA perspective. , 2003, Clinical and experimental rheumatology.

[119]  S. Gabriel,et al.  Features of male versus female patients undergoing surgery for osteoarthritis: comment on two recent articles. , 1995, Arthritis and rheumatism.

[120]  M. Dougados,et al.  Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide , 2002, Annals of the rheumatic diseases.

[121]  A. Silman,et al.  The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. , 1994, British journal of rheumatology.

[122]  L. V. D. van de Putte,et al.  Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. , 1997, British journal of rheumatology.

[123]  M. Dougados,et al.  Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study , 2004, Annals of the rheumatic diseases.

[124]  James M Robins,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[125]  A. Masi.  Articular patterns in the early course of rheumatoid arthritis. , 1983, The American journal of medicine.

[126]  E. Keystone,et al.  Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction? , 2005, Arthritis and rheumatism.

[127]  M. Dougados,et al.  Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components , 1999, Annals of the rheumatic diseases.

[128]  P. Hannonen,et al.  Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial , 1999, The Lancet.

[129]  Alexander Fraser,et al.  Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-contro , 2005, Arthritis and rheumatism.

[130]  D. Green,et al.  Rheumatoid arthritis and p53: how oxidative stress might alter the course of inflammatory diseases. , 2000, Immunology today.

[131]  John Han,et al.  Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. , 2006, Arthritis and rheumatism.

[132]  J. O'dell,et al.  Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone. , 2006, Arthritis and rheumatism.

[133]  D Loreck,et al.  Arthritis of the finger joints: a comprehensive approach comparing conventional radiography, scintigraphy, ultrasound, and contrast-enhanced magnetic resonance imaging. , 1999, Arthritis and rheumatism.

[134]  J. Jacobs,et al.  Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial) , 2007, Annals of the rheumatic diseases.

[135]  D. M. van der Heijde,et al.  Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. , 2004, Arthritis and rheumatism.

[136]  M. V. van Leeuwen,et al.  Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. , 1998, British Journal of Rheumatology.

[137]  H. Genant,et al.  Repair of erosions in rheumatoid arthritis does occur. Results from 2 studies by the OMERACT Subcommittee on Healing of Erosions. , 2003, The Journal of rheumatology.

[138]  J. Ilonen,et al.  Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. , 2002, Arthritis and rheumatism.

[139]  D. Heijde,et al.  Older versus younger onset rheumatoid arthritis: results at onset and after 2 years of a prospective followup study of early rheumatoid arthritis. , 1991 .

[140]  H. J. Moens,et al.  Comparison of the sensitivity and specificity of the 1958 and 1987 criteria for rheumatoid arthritis. , 1992 .

[141]  V. Strand,et al.  The effects of disease-modifying anti-rheumatic drugs on the Health Assessment Questionnaire score. Lessons from the leflunomide clinical trials database. , 2002, Rheumatology.

[142]  F. Breedveld,et al.  The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. , 2006, Arthritis and rheumatism.